| 摘要 |
NZ 590327 Disclosed is a method of making a diagnosis in a patient that has been treated with, or is a candidate to be treated with, an Activin Receptor Type IIa (ActRIIa) polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 3 as defined in the complete specification. The disclosed method comprises: monitoring in a sample obtained from the patient one or more hematologic parameters selected from red blood cell levels, haemoglobin levels, iron stores, transferrin saturation, ferritin levels, and haematocrit levels; determining whether the sample indicates that the patient has one or more hematological parameters selected from: a red blood cell level greater than the normal range for patients of similar age and sex; a hemoglobin level of greater than the normal range for patients of similar age and sex; iron stores that are lower than the normal range for patients of similar age and sex; a transferrin saturation of less than 20%; a ferritin level of less than 100 ng/ml; and a hematocrit level greater than the normal range for patients of similar age and sex; and making a diagnosis that dosing with the ActRIIa polypeptide be reduced, delayed, or terminated in the patient for whom a determination in step (ii) is affirmative. |
